Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients

Bone Marrow Transplantation

Volumn 44, Issue 1, 2009, Pages 35-41

  Chae, Y S ^a   Kim, J G ^a   Moon, J H ^a   Kim, S N ^a   Lee, S J ^a   Kim, Y J ^a   Sohn, S K ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; CALCIUM CARBONATE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; METRONIDAZOLE; STEROID; TACROLIMUS; ZOLEDRONIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE DENSITY; BONE DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG USE; FEMALE; FEMUR NECK; GRAFT RECIPIENT; HLA MATCHING; HUMAN; LUMBAR SPINE; MALE; MUCOSA INFLAMMATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHRONIC DISEASE; DIPHOSPHONATES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; PILOT PROJECTS; STEM CELL TRANSPLANTATION; STEROIDS; TRANSPLANTATION, HOMOLOGOUS;

EID: 67651093855     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.414     Document Type: Article

References (32)

1. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S et al Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: Long-term follow-up of a prospective study. Br J Haematol 2003; 121: 462-468.
2. Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: Effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23: 355-361.
3. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: A prospective study. Biol Blood Marrow Transplant 2001; 7: 257-264.
4. Tauchmanova L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G et al. Long-lasting bone damage detected by dual-energy X-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002; 87: 5058-5065.
5. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: Clinical aspects. Biol Blood Marrow Transplant 2000; 6: 175-181.
6. D'Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J 2006; 36: 600-603.
7. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: A long-term follow-up. Blood 2004; 103: 3635-3643.
8. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005; 90: 3877-3885.
9. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: Comparison with BuCy2. Bone Marrow Transplant 2007; 40: 541-547.
10. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939-948.
13. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
14. Kanis JA, Seeman E, Johnell O, Rizzoli R, Delmas P. The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 2005; 16: 456-459, discussion 579-80.
15. Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: A mechanism for post-bone marrow transplantation osteopenia. Cancer 2001; 92: 2419-2428.
16. Marcus R, Wong M, Heath III H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16-37.
17. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-3617.
18. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-2026.
19. Massenkeil G, Fiene C, Rosen O, Michael R, Reisinger W, Arnold R. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: Standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001; 15: 1701-1705.
20. Tauchmanova L, De Simone G, Musella T, Orio F, Ricci P, Nappi C et al Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 81-88.
21. Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B et al Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005; 90: 627-634.
22. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92-103.
23. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745.
24. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol 2001; 28 (2 Suppl 6): 35-44.
25. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J et al. Zoledronic acid treatment of 5T2 MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482-492.
26. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96 384-392.
27. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-168.
28. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14: 841-844.
29. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-1134.
30. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y et al. The third-generation bisphosphonate zole-dronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003; 102: 2229-2235.
31. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004; 79: 37-43.
32. Fiegl M, Juergens M, Hiddemann W, Braess J. Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. Leuk Res 2007; 31: 531-539.